On Thursday, QSM Asset Management disclosed a significant buy of Pfizer (PFE -0.18%), adding shares worth an estimated $6.8 million in the third quarter.
What Happened
QSM Asset Management increased its position in Pfizer, adding 276,899 shares in the third quarter of 2025, according to a filing with the Securities and Exchange Commission released on Thursday. The estimated value of the purchase, based on the period’s average share price, was approximately $6.8 million for the quarter ended September 30. This brought the firm’s total Pfizer holdings to 460,743 shares, worth $11.3 million.
What Else to Know
QSM’s Pfizer position now represents 8.1% of the fund’s 13F assets under management.
Top holdings after the filing:
- NYSE:ZBH: $12.9 million (9.2% of AUM)
- NASDAQ:INTC: $12.2 million (8.7% of AUM)
- NASDAQ:VTRS: $11.6 million (8.3% of AUM)
- NYSE:RIO: $11.5 million (8.2% of AUM)
- NYSE:PFE: $11.3 million (8.1% of AUM)
As of Thursday morning, Pfizer shares were priced at $24.52, down 17% over the past year and trailing the S&P 500, which is up 15% over the same period.
Company Overview
| Metric | Value |
|---|---|
| Revenue (TTM) | $63.8 billion |
| Net income (TTM) | $10.8 billion |
| Dividend yield | 7% |
| Price (as of Thursday mornin) | $24.52 |
Company Snapshot
- Pfizer offers a diversified portfolio of biopharmaceutical products, including medicines and vaccines for cardiovascular, infectious, immunological, and rare diseases.
- The pharma giant generates revenue primarily through the discovery, development, manufacturing, and global distribution of branded pharmaceuticals and vaccines.
- It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and disease control and prevention centers.
Pfizer is a global leader in the biopharmaceutical industry, with a broad product lineup spanning innovative medicines and vaccines. The company leverages its research and development capabilities, strategic collaborations, and global distribution network to maintain a competitive position in the healthcare sector.
Foolish Take
QSM Asset Management’s $6.8 million addition to its stake in Pfizer (NYSE: PFE) deepens its exposure to high-dividend, undervalued healthcare names—a move consistent with its value-focused investment strategy aimed at generating steady returns over five-year cycles. Pfizer, one of the firm’s top five holdings, accounts for 8.1% of its portfolio alongside companies like Zimmer Biomet and Intel, reflecting a tilt toward established, cash-generating global leaders.
Pfizer’s most recent quarter showed signs of stabilization following pandemic-era volatility. The company reported $14.7 billion in revenue, up 10% year over year. Management reaffirmed full-year revenue guidance and guidance for adjusted earnings per share by $0.10 to about $3 per share. The move also comes weeks after the company announced a landmark drug-pricing agreement alongside President Donald Trump.
For long-term investors, QSM’s conviction highlights the potential upside in Pfizer’s depressed valuation and 7% dividend yield. With a robust balance sheet, expanding drug portfolio, and renewed focus on efficiency, Pfizer offers a blend of income and rebound potential that fits QSM’s long-term, value-driven investment thesis.
Glossary
Assets under management (AUM): The total market value of investments managed by a fund or investment firm.
13F reportable assets: Securities that investment managers must disclose in quarterly SEC Form 13F filings, typically U.S.-listed stocks and certain options.
Position: The amount of a particular security or asset owned by an investor or fund.
Stake: The ownership interest or share held in a company by an investor or fund.
Dividend yield: Annual dividend payments divided by the stock's current price, expressed as a percentage.
Trailing twelve months (TTM): The 12-month period ending with the most recent quarterly report.
Biopharmaceutical: Relates to drugs and therapies developed using biological sources and biotechnology.
Wholesalers: Companies that buy products in bulk from manufacturers to sell to retailers or other businesses.
Strategic collaborations: Partnerships between companies to achieve shared business goals, often in research, development, or distribution.
